The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects

Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to Paritaprevir in Non-structural Viral Protein 3 (NS3)

Time frame: For approximately 5 years

Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to Ombitasvir in Non-structural Viral Protein 5A (NS5A)

Time frame: For approximately 5 years

Percentage of participants with hepatocellular carcinoma

Time frame: Up to 60 month after completion of the 2D treatment in M12-536 or M13-004

Number of participants with serious adverse events (SAEs)

All serious adverse events will be monitored during the observation period.

Time frame: Up to 60 month after completion of the 2D treatment in M132-536 or M13-004 study

Hepatitis C virus ribonucleic acid (HCV RNA) levels

HCV RNA levels in plasma

Time frame: 18, 24, 30, 36, 42, 48, 52 months after completion of the 2D treatment in M12-536 or M13-004 study